Page 105 - 《中国药房》2025年19期

[20] GERFAUD-VALENTIN M，MAUCORT-BOULCH D， [33] ÇOLAK S，TEKGÖZ E，MAMMADOV M，et al. Biologi‐
HOT A，et al. Adult-onset Still disease：manifestations， cal treatment in resistant adult-onset Still’s disease：a
treatment，outcome，and prognostic factors in 57 patients single-center，retrospective cohort study[J]. Arch Rheuma‐
[J]. Medicine （Baltimore），2014，93（2）：91-99. tol，2021，37（1）：11-18.
[21] CAVALLI G，FRANCHINI S，AIELLO P，et al. Efficacy [34] BINDOLI S，GALOZZI P，DORIA A，et al. Intravenous
and safety of biological agents in adult-onset Still’s anakinra to curb cytokine storm in adult-onset Still’s
disease[J]. Scand J Rheumatol，2015，44（4）：309-314. disease and in macrophage activation syndrome：a case
[22] ORTIZ-SANJUÁN F，BLANCO R，RIANCHO- series[J]. Joint Bone Spine，2023，90（2）：105524.
ZARRABEITIA L，et al. Efficacy of anakinra in refrac‐ [35] BITIK B，ŞENTURK M，KIBAROGLU S，et al. Intrave‐
tory adult-onset Still’s disease：multicenter study of 41 pa‐ nous anakinra for treating macrophage activation syn‐
tients and literature review[J]. Medicine （Baltimore）， drome in adult-onset Still’s disease[J]. Eur J Case Rep In‐
2015，94（39）：e1554. tern Med，2024，11（11）：004788.
[23] ROSSI-SEMERANO L，FAUTREL B，WENDLING D， [36] KERNDER A，FILLA T，FRIEDRICH R，et al. First-line
et al. Tolerance and efficacy of off-label anti-interleukin-1 biological versus conventional synthetic disease-
treatments in France：a nationwide survey[J]. Orphanet J modifying antirheumatic drug therapy in adult-onset Still’s
Rare Dis，2015，10：19. disease：a multicentre，retrospective，propensity weighted
[24] LENERT A，YAO Q P. Macrophage activation syndrome cohort study[J]. Lancet Rheumatol，2025，7（6）：e415-e423.
complicating adult onset Still’s disease：a single center [37] KILIC B，PARLAR K，KARUP S，et al. Anakinra in the
case series and comparison with literature[J]. Semin Ar‐ management of adult-onset Still’s disease：a single-center
thritis Rheum，2016，45（6）：711-716. experience[J]. Intern Emerg Med，2025，20（1）：131-138.
[25] VITALE A，INSALACO A，SFRISO P，et al. A snapshot [38] VITALE A，CAVALLI G，RUSCITTI P，et al. Comparison
on the on-label and off-label use of the interleukin-1 in‐ of early vs. delayed anakinra treatment in patients with
hibitors in Italy among rheumatologists and pediatric rheu‐ adult onset Still’s disease and effect on clinical and
matologists：a nationwide multi-center retrospective obser‐ laboratory outcomes[J]. Front Med （Lausanne） ，
vational study[J]. Front Pharmacol，2016，7：380. 2020，7：42.
[26] SFRISO P，PRIORI R，VALESINI G，et al. Adult-onset [39] MEHTA P，CRON R Q，HARTWELL J，et al. Silencing
Still’s disease：an Italian multicentre retrospective obser‐ the cytokine storm：the use of intravenous anakinra in hae‐
vational study of manifestations and treatments in 245 pa‐ mophagocytic lymphohistiocytosis or macrophage activation
tients[J]. Clin Rheumatol，2016，35（7）：1683-1689. syndrome[J]. Lancet Rheumatol，2020，2（6）：e358-e367.
[27] COLAFRANCESCO S，PRIORI R，VALESINI G，et al. [40] COLAFRANCESCO S，MANARA M，BORTOLUZZI A，
Response to interleukin-1 inhibitors in 140 Italian patients et al. Management of adult-onset Still’s disease with inter‐
with adult-onset Still’s disease：a multicentre retrospec‐ leukin-1 inhibitors：evidence- and consensus-based state‐
tive observational study[J]. Front Pharmacol，2017，8：369. ments by a panel of Italian experts[J]. Arthritis Res Ther，
[28] NÉEL A，WAHBI A，TESSOULIN B，et al. Diagnostic 2019，21（1）：275.
and management of life-threatening adult-onset Still [41] BINDOLI S，DE MATTEIS A，MITROVIC S，et al. Effi‐
disease：a French nationwide multicenter study and sys‐ cacy and safety of therapies for Still’s disease and macro‐
tematic literature review[J]. Crit Care，2018，22（1）：88. phage activation syndrome （MAS）：a systematic review
[29] VERCRUYSSE F，BARNETCHE T，LAZARO E，et al. informing the EULAR/PReS guidelines for the manage‐
Adult-onset Still’s disease biological treatment strategy ment of Still’s disease[J]. Ann Rheum Dis，2024，83（12）：
may depend on the phenotypic dichotomy[J]. Arthritis Res 1731-1747.
Ther，2019，21（1）：53. [42] SETTAS L D，TSIMIRIKAS G，VOSVOTEKAS G，et al.
[30] VASTERT S J，JAMILLOUX Y，QUARTIER P，et al. Reactivation of pulmonary tuberculosis in a patient with
Anakinra in children and adults with Still’s disease[J]. rheumatoid arthritis during treatment with IL-1 receptor
Rheumatology （Oxford），2019，58（Suppl. 6）：9-22. antagonists （anakinra）[J]. J Clin Rheumatol，2007，13
[31] RUSCITTI P，URSINI F，SOTA J，et al. The reduction of （4）：219-220.
concomitant glucocorticoids dosage following treatment [43] MIGKOS M P，SOMARAKIS G A，MARKATSELI T E，
with IL-1 receptor antagonist in adult onset Still’s et al. Tuberculous pyomyositis in a rheumatoid arthritis pa‐
disease. A systematic review and meta-analysis of observa‐ tient treated with anakinra[J]. Clin Exp Rheumatol，2015，
tional studies[J]. Ther Adv Musculoskelet Dis，2020，12： 33（5）：734-736.
1759720X20933133. [44] 国家传染病医学中心，复旦大学附属华山医院. 免疫抑
[32] MONTEAGUDO L A，BOOTHBY A，GERTNER E. Con‐ 制剂与结核潜伏感染激活的临床专家共识：2025 版[J].
tinuous intravenous anakinra infusion to calm the cytokine 中华传染病杂志，2024，42（12）：715-735.
storm in macrophage activation syndrome[J]. ACR Open （收稿日期：2025-06-09 修回日期：2025-09-11）
Rheumatol，2020，2（5）：276-282. （编辑：舒安琴）

中国药房 2025年第36卷第19期 China Pharmacy 2025 Vol. 36 No. 19 · 2447 ·